Literature DB >> 3102507

Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells.

Y J Wan, B M Orrison, R Lieberman, P Lazarovici, K Ozato.   

Abstract

Mouse embryonal carcinoma F9 cells, upon treatment with interferons (IFNs), express major histocompatibility (MHC) Class I antigens, which are otherwise not expressed in these cells. Both IFN-gamma and IFN-alpha/beta increase the steady-state level of Class I mRNA within 60 min of the treatment which leads to the subsequent surface expression of the H-2Kb and H-2Db antigens, suggesting that undifferentiated F9 cells express IFN receptors. IFNs induce Class I antigen expression in F9 cells in a highly selective manner: unlike retinoic acid treatment which also stimulates the antigen expression, IFNs induce neither morphological differentiation, increased binding of epidermal growth factor, nor reduction of expression of stage specific embryonic antigen. The effect of IFNs is reversible; removal of IFNs, even after prolonged exposures, results in a rapid loss of the Class I gene expression. Further, Class I mRNA induction is not inhibited by cycloheximide, suggesting possible independence from de novo protein synthesis. This Class I antigen induction in F9 cells is reminiscent of that observed in somite stage mouse embryos by IFN treatment and may offer a model system to study activation of MHC genes during development.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102507     DOI: 10.1002/jcp.1041300214

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  16 in total

1.  Retinoic acid and microRNA.

Authors:  Lijun Wang; Atharva Piyush Rohatgi; Yu-Jui Yvonne Wan
Journal:  Methods Enzymol       Date:  2020-03-28       Impact factor: 1.600

2.  Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence.

Authors:  Y Shirayoshi; P A Burke; E Appella; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

3.  Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.

Authors:  A Eisenthal; Y Skornick; I Ron; V Zakuth; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

4.  A burst of c-fos gene expression in the mouse occurs at birth.

Authors:  J W Kasik; Y J Wan; K Ozato
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

5.  In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.

Authors:  R K Puri; P Leland
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

6.  A regulatory element in the beta 2-microglobulin promoter identified by in vivo footprinting.

Authors:  M Lonergan; A Dey; K G Becker; P D Drew; K Ozato
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

7.  Binding of multiple nuclear factors to the 5' upstream regulatory element of the murine major histocompatibility class I gene.

Authors:  Y Shirayoshi; J Miyazaki; P A Burke; K Hamada; E Appella; K Ozato
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

8.  Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.

Authors:  R K Puri; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription.

Authors:  N Nelson; M S Marks; P H Driggers; K Ozato
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

10.  Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.

Authors:  P J Arroyo; J A Bash; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.